Effect of boswellia (Boswellia serrata L.) supplementation on glycemic markers and lipid profile in type 2 diabetic patients: a systematic review and meta-analysis.
- 2024-10-10
- Frontiers in clinical diabetes and healthcare 5
- Mehdi Karimi
- Kimia Vakili
- Pegah Rashidian
- Seyedeh-Kiana Razavi-Amoli
- Matin Akhbari
- Kimia Kazemi
- PubMed: 39449720
- DOI: 10.3389/fcdhc.2024.1466408
Study Design
- Type
- Systematic Review
- Sample size
- n = 287
- Population
- patients with T2DM
- Methods
- comprehensive search on PubMed, Web of Science, and Scopus; meta-analysis using Stata
Background
Type 2 diabetes mellitus (T2DM) is a significant global health challenge whose prevalence is projected to increase alarmingly. Recently, due to better safety and fewer adverse effects, herbal medicines have been used to manage T2DM. This study aimed to evaluate the efficacy of boswellia in improving glycemic markers and lipid profiles in T2DM patients.Methods
A comprehensive search was conducted on the PubMed, Web of Science, and Scopus databases for all relevant studies published up to April 30, 2024. The effects of boswellia supplementation were evaluated using glycemic markers and lipid profiles. The data were extracted and meta-analyzed using Stata software.Results
This meta-analysis included five studies with a total of 287 patients with T2DM. It was found that boswellia in patients with T2DM compared to the placebo or control group significantly reduced hemoglobin A1C (HbA1C) (SMD: -1.01; 95%CI: -1.55 to -0.46; P=0.00), total cholesterol (TC) (SMD: -0.44; 95%CI: -0.68 to -0.21; P=0.00), Triglycerides (TG) (SMD: -0.42; 95%CI: -0.66 to -0.19); P=0.00) and low-density lipoprotein (LDL) (SMD: -0.43; 95%CI: -0.73 to -0.12); P=0.006) levels, while reduced fasting blood glucose (FBG) but it was not significant (SMD: -1.34, 95%CI: -2.68 to 0.00; P=0.05). Notably, it did not affect high-density lipoprotein (HDL) (SMD: 0.56, 95%CI: -0.14 to -1.26; P=0.118).Conclusion
In summary, boswellia supplementation has the potential to improve glycemic markers and lipid profiles in patients with T2DM. It may help diabetic patients in addition to a controlled diet and other treatments.Systematic review registration
crd.york.ac.uk/PROSPERO/display_record.php?RecordID=538347, identifier CRD42024538347.Research Insights
significantly reduced hemoglobin A1C (HbA1C) (SMD: -1.01; 95%CI: -1.55 to -0.46; P=0.00)
- Effect
- Beneficial
- Effect size
- Large
significantly reduced low-density lipoprotein (LDL) (SMD: -0.43; 95%CI: -0.73 to -0.12); P=0.006
- Effect
- Beneficial
- Effect size
- Moderate
significantly reduced total cholesterol (TC) (SMD: -0.44; 95%CI: -0.68 to -0.21; P=0.00)
- Effect
- Beneficial
- Effect size
- Moderate
significantly reduced Triglycerides (TG) (SMD: -0.42; 95%CI: -0.66 to -0.19); P=0.00
- Effect
- Beneficial
- Effect size
- Moderate